Á¦18ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö : 2023-04-07
±³À°ÀÏÀÚ : 2023-04-07
±³À°Àå¼Ò : ¿©¼öÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ : Á¦18ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ
´ã´çÀÚ : ±è¹Ì¼±
¿¬¶ôó : 02-575-3825
À̸ÞÀÏ : katrd@hanmail.net
±³À°Á¾·ù : ³»°úÀÇÇб³À°, ±âŸ
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : Àü¶ó³²µµ
±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í »çÀüµî·Ï : Àü¹®ÀÇ, ÀϹÝÀÇ 30,000¿ø / Àü°øÀÇ, ±âŸ 20,000¿ø ÇöÀåµî·Ï : Àü¹®ÀÇ, ÀϹÝÀÇ 40,000 / Àü°øÀÇ, ±âŸ 30,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-07 °ÀÇ½Ç A 12:40~13:40 ¡°3rd EGFR TKI ·º¶óÀÚ¿Í °ü·ÃµÈ ÅäÇÈ¡± ±èÀº¿µ(¿¬¼¼ÀÇ´ë ³»°ú)
±³À°½Ã°£ 04-07 °ÀÇ½Ç A 14:10~14:40 1. What Is the Best Treatment Strategy for Stage III NSCLC? Á¤Àç¿í(Ãæ³²ÀÇ´ë ³»°ú)
±³À°½Ã°£ 04-07 °ÀÇ½Ç A 14:40~15:10 2. Treatment of NSCLC with Rare Mutations À±¼ºÈÆ(ºÎ»êÀÇ´ë ³»°ú)
±³À°½Ã°£ 04-07 °ÀÇ½Ç A 15:10~15:40 3. Safe Use of Immune Checkpoint Inhibitors in Worrisome Comorbidities ¹Úµ¿¿ø(ÇѾçÀÇ´ë ³»°ú)
±³À°½Ã°£ 04-07 °ÀÇ½Ç A 16:00~16:30 4. Management of Problematic Metastatic Diseases to Brain and Bone ÃÖ¼±ÇÏ(°æºÏÀÇ´ë ³»°ú)
±³À°½Ã°£ 04-07 °ÀÇ½Ç A 16:30~17:00 5. Management of Oligometastatic/Oligoprogressive Disease Áö¿øÁØ(¿ï»êÀÇ´ë ³»°ú)
±³À°½Ã°£ 04-07 °ÀÇ½Ç A 17:00~17:30 6. Treatment of Lung Cancer in Elderly Patients ¿ÀÇüÁÖ(Àü³²ÀÇ´ë ³»°ú)
±³À°½Ã°£ 04-07 °ÀÇ½Ç A 17:30~18:10 ¡°Expanding the Horizons: Type 2 Targeting Dupilumab Therapy in Severe Asthma and Beyond¡± ½Å¼±Çý(¼º±Õ°üÀÇ´ë ³»°ú)